![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bristol Myers Squibb to Pay $13.1 Billion for MyoKardia
Bristol Myers Squibb to Pay $13.1 Billion for MyoKardia
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
October 6, 2020
Bristol Myers Squibb (BMS) is expanding its lineup of cardiovascular drugs by acquiring Brisbane, Calif., drugmaker MyoKardia for $13.1 billion in a transaction that is expected to close before year’s end.
The deal gives BMS mavacamten, MyoKardia’s investigational treatment for obstructive hypertrophic cardiomyopathy, a chronic heart disease afflicting up to 200,000 individuals in the U.S. and the EU.
The companies expect to file a new drug application with the FDA for that indication in the first quarter of 2021, and BMS also plans to seek additional approvals for the drug.
Upcoming Events
-
21Oct